ArticleFrontiers in nutrition2025
The effect of aqueous extract of Iranian oak (
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Beta-thalassemia major patients often require regular blood transfusions, leading to iron overload, oxidative stress, and disturbances in lipid metabolism. The common use of vitamins and iron chelators helps mitigate some of these effects, but lipid profile abnormalities persist. The oak fruit ( Materials and methods: This randomized, double-blind, placebo-controlled clinical trial included 60 beta-thalassemia major patients (29 males, 31 females; age 10-60 years) who regularly received blood transfusions and deferoxamine. Participants were divided into two groups: the intervention group received Iranian oak extract capsules (300 mg/day), and the control group received placebo capsules for 3 months. Lipid profiles (cholesterol, triglycerides, HDL, LDL) and liver enzymes (ALT, AST) were measured before and after the intervention. Results: The control group exhibited a significant increase in triglyceride levels (from 167 to 184 mg/dL, Conclusion: The aqueous extract of Iranian oak demonstrated potential lipid-modulating effects by preventing triglyceride increases and reducing cholesterol levels in beta-thalassemia major patients. These findings suggest that the antioxidant properties of the oak extract may help manage lipid abnormalities associated with iron overload, improving cardiovascular risk profiles in these patients. Further studies with larger sample sizes and extended follow-up are recommended to confirm these benefits. Clinical trial tegistration: http://www.irct.ir, identifier IRCT2015101411819N4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.